SANTARUS, INC. 
By SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)-- Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) announced that new data from a pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.
"RUCONEST has the potential to be an important addition to the therapeutic options available for the treatment of acute attacks of HAE based on the encouraging clinical data observed to date," said Marc Riedl, M.D., Section Head Department of Clinical Immunology and Allergy, University of California, Los Angeles and lead author of the poster.
The poster is titled, Recombinant Human C1 Inhibitor for Treatment of Acute Attacks of Hereditary Angioedema: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. The primary endpoint and safety data from the study are summarized below:
Time to Beginning of Relief of Symptoms | ||||||||||||||||||||||||||||||
| Median (95% CI), minutes | p-value* | |||||||||||||||||||||||||||||
| Placebo (N=31) | RUCONEST (N=44) | |||||||||||||||||||||||||||||
| Based on Treatment Effect Questionnaire | ||||||||||||||||||||||||||||||
| (TEQ) (Primary Endpoint) | 152 (93, -) | 90 (61, 150) | 0.031 | |||||||||||||||||||||||||||
| Based on Visual Analog Scale (VAS) | ||||||||||||||||||||||||||||||
|
Decrease
Share
© Publicnow - 2013
| ||||||||||||||||||||||||||||||
